Epidermal growth factor (EGF) is a neurotrophic factor that plays an important role in Parkinson’s disease (PD). We measured plasma EGF level in PD, essential tremor (ET) and normal controls toinvestigate whether it changes in PD and whether it is associated with motor and non-motor symptoms of PD. 100 patients with PD, 40 patients with ET as disease control and 76 healthy persons were enrolled in the present study. Motor and non-motor symptoms were assessed by different scales. Plasma EGF levels of three groups were measured by enzyme-linked immunosorbent assay kit. Spearman test and linear logistics regression model were used to test the correlation of EGF with motor and non-motor symptoms of PD. Plasma EGF level was significantly decreased in early PD patients compared with normal control, butnot in advanced PD patients. Interestingly, plasma EGF level was significantly increased in advanced PD and total PD patients compared with ET patients, but not in early PD patients. In addition, plasma EGF level was correlated with UPDRS-III scores in PD. Also plasma EGF level was correlated with UPDRS-III scores and NMS scores in early PD.Our results suggested that plasma EGF decreased in the early stage of PD and increased later on in the PD disease course. Also, plasma EGF level was increased significantly in PD compared with ET patients and correlated with motor and non-motor symptoms in early PD.
Table 1 Demographic features and EGF level of PD, ET and controls
Table 2 Demographic features, clinical characteristics and serum EGF level in PD patients and control
Figure 1. Correlation of plasma EGF with motor and non-motor symptoms of PD.A. Plasma EGF correlated with UPDRS-III scores in PD patients. B. Plasma EGF correlated with UPDRS-III scores in early PD. C. Plasma EGF correlated with NMS scores in early PD.
Weissmiller AM, Wu C (2012). Current advances in using neurotrophic factors to treat neurodegenerative disorders. Translational neurodegeneration, 1(1):14.
Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & therapeutics, 138(2):155-175.
Gomez-Pinilla F, Knauer DJ, Nieto-Sampedro M (1998). Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization. Brain research, 438(1-2):385-390.
Iwakura Y, Piao YS, Mizuno M, et al (2005). Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. Journal of neurochemistry, 93(4):974-983.
Grainne C.O Keeffe, Pam Tyers, Dag Aarslandet al (2009). Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. PNAS, 106: 8754-8759
Pezzoli G, Zecchinelli A, Ricciardi S, et al (1991). Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats. Movement disorders: official journal of the Movement Disorder Society, 6(4):281-287.
Chen-Plotkin AS, Hu WT, Siderowf A, et al (2011). Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of neurology, 69(4):655-663.
Kuhlenbäumer G, Hopfner F, Deuschl G (2014).Genetics of essential tremor: meta-analysis and review.Neurology, 82(11):1000-7.
Delay C, Tremblay C, Brochu E, et al (2014).Increased LINGO1 in the cerebellum of essential tremor patients.Mov Disord. Feb 14. [Epub ahead of print]
Inoue H, Lin L, Lee X, et al (2007). Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.PNAS, 104(36):14430-14435.
Deuschl G, Bain P, Brin M (1998). Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Movement disorders: official journal of the Movement Disorder Society, 13 Suppl 3:2-23.
Chen W, Chen S, Kang WY, et al (2012). Application of odor identification test in Parkinson's disease in China: a matched case-control study. Journal of the neurological sciences, 316(1-2):47-50.
Booij J, Tissingh G, Boer GJ, et al (1997). [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 62(2):133-140.
Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P (2013). The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Functional neurology, 28(1):13-17.
Babij R, Lee M, Cortes E, Vonsattel JP, Faust PL, Louis ED (2013). Purkinje cell axonal anatomy: quantifying morphometric changes in essential tremor versus control brains. Brain: a journal of neurology, 136(Pt 10):3051-3061.
Birecree E, King LE, Jr., Nanney LB (1991). Epidermal growth factor and its receptor in the developing human nervous system. Brain research Developmental brain research, 60(2):145-154.
Kuo SH, Tang G, Louis ED, et al (2013). Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta neuropathologica, 125(6):879-889.
Zhou ZD, Sathiyamoorthy S, Tan EK (2012). LINGO-1 and Neurodegeneration: Pathophysiologic Clues for Essential Tremor. Tremor and other hyperkinetic movements, 2.pii: tre-02-51-249-1.
Pellecchia MT, Santangelo G, Picillo M, et al (2013). Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. Journal of neurology, 260(2):438-444.
Rocha NP, Teixeira AL, Scalzo PL, et al (2014). Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society, 29(4):527-31.